Business Wire

Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing ...
Healio

Phase 2 Osprey, Apteryx studies of QLS-111 meet all endpoints

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with primary open-angle glaucoma or ocular ...
PE Hub

LDC exits J&J to Waterland-backed QLS

LDC backed J&J in March 2020 with £11m investment J&J grew revenues by 415% to £74m over the last five years QLS is a Netherlands-based ecommerce fulfilment specialist LDC has exited its stake in J&J ...
Business Wire

Qlaris Bio Announces Positive Topline Data From Two Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two ...